Get the Stockscreener App
68.28
0.23%
0.185
Insmed Inc stock is traded at $68.28, with a volume of 483.93K.
It is up +0.23% in the last 24 hours and down -5.57% over the past month.
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
See More
Previous Close:
$68.09
Open:
$67.85
24h Volume:
483.93K
Relative Volume:
0.29
Market Cap:
$12.13B
Revenue:
$315.49M
Net Income/Loss:
$-746.89M
P/E Ratio:
-12.96
EPS:
-5.27
Net Cash Flow:
$-588.55M
1W Performance:
-3.81%
1M Performance:
-5.57%
6M Performance:
+167.10%
1Y Performance:
+174.63%
1-Day Range:
$67.42
$68.73
1-Week Range:
$65.95
$71.37
52-Week Range:
$21.92
$80.53
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed's SWOT analysis: rare disease biotech stock poised for growth By Investing.com - Investing.com UK
Insmed Incorporated (NASDAQ:INSM) Shares Sold by New York State Common Retirement Fund - MarketBeat
INSMInsmed, Inc. Latest Stock News & Market Updates - StockTitan
Insmed (INSM) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Insmed Incorporated (NASDAQ:INSM) Shares Bought by Emerald Advisers LLC - MarketBeat
Insmed's Q3 Loss Wider Than Expected, Sales In Line With Estimates - MSN
Insmed (NASDAQ:INSM) Announces Earnings Results - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Q3 2024 Earnings Call Transcript - Insider Monkey
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates - MSN
Earnings call: Insmed reports strong Q3 growth, eyes brensocatib launch - Investing.com
Earnings call: Insmed reports strong Q3 growth, eyes brensocatib launch By Investing.com - Investing.com UK
Do You Believe in the Growth Potential of Insmed (INSM)? - Yahoo Finance
Truist Financial Reaffirms Buy Rating for Insmed (NASDAQ:INSM) - MarketBeat
Insmed Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus.com
Insmed Inc (INSM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Insmed Inc (INSM) Q3 2024 Earnings Call Highlights: Strong Reven - GuruFocus.com
Insmed: Q3 Earnings Snapshot - The Advocate
Insmed (INSM) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update - PR Newswire
How to play biotech stocks: Insmed and Wave Life Sciences - Yahoo Finance
Insmed Incorporated (NASDAQ:INSM) Shares Bought by China Universal Asset Management Co. Ltd. - MarketBeat
Novo Holdings A S Lowers Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Shares Acquired by Creative Planning - MarketBeat
Insmed Ranks No. 1 on Science’s 2024 Top Biopharma Employers List - njbmagazine.com
Assenagon Asset Management S.A. Raises Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed's SWOT analysis: stock poised for growth amid challenges - Investing.com India
Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List - Citizentribune
Insmed's SWOT analysis: stock poised for growth amid challenges By Investing.com - Investing.com Australia
Insmed Incorporated (NASDAQ:INSM) Shares Sold by Hennion & Walsh Asset Management Inc. - MarketBeat
Insmed Unites Across Communities Around the World During Third Annual Global Day of Good - StockTitan
Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024 - Citizentribune
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
UBS Initiates Coverage of Insmed (INSM) with Buy Recommendation - MSN
Short Interest in Insmed Incorporated (NASDAQ:INSM) Expands By 8.0% - MarketBeat
Dimensional Fund Advisors LP Acquires Shares of 12,089 Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Essex Investment Management Co. LLC Has $5.64 Million Holdings in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Truist Securities raises Insmed stock price target as confidence grows in brensocatib launch - Investing.com Canada
Truist Financial Increases Insmed (NASDAQ:INSM) Price Target to $100.00 - MarketBeat
Insmed Inc (INSM) Q2 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Insmed (NASDAQ:INSM) Given New $86.00 Price Target at Bank of America - MarketBeat
TD Cowen reaffirms Buy rating on Insmed stock following CHEST conference update - Investing.com Canada
Investing in Insmed (NASDAQ:INSM) five years ago would have delivered you a 308% gain - Simply Wall St
Handelsbanken Fonder AB Has $3.18 Million Stock Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results - The Malaysian Reserve
Insmed reports consistent brensocatib benefits in bronchiectasis study By Investing.com - Investing.com Canada
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Michael Alexander | Chief Legal Officer |
Sep 13 '24 |
Sale |
74.35 |
27,871 |
2,072,223 |
67,856 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 13 '24 |
Option Exercise |
34.03 |
26,969 |
917,755 |
133,103 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 16 '24 |
Option Exercise |
34.03 |
13,436 |
457,227 |
119,570 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 12 '24 |
Option Exercise |
34.03 |
635 |
21,609 |
106,769 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 13 '24 |
Sale |
74.90 |
26,969 |
2,019,978 |
106,134 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 16 '24 |
Sale |
74.92 |
13,436 |
1,006,625 |
106,134 |
| Flammer Martina M.D. | Chief Medical Officer |
Sep 12 '24 |
Sale |
74.92 |
635 |
47,574 |
106,134 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):